A contract extension has been signed with an existing large pharma client. This builds upon the contract awarded in June 2024 and uses Physiomics’s proprietary Virtual Tumour platform to model the client’s targeted oncology agents in combination with other modalities helping inform dose and scheduling decisions. The contract extension continues this work and supports the client’s expansion into new oncology indications. We understand that Physiomics has made a positive impact on the client’s ....